HRP20191003T1 - Derivati 4-okso-3,4-dihidro-1,2,3-benzotriazina kao modulatori gpr139 - Google Patents
Derivati 4-okso-3,4-dihidro-1,2,3-benzotriazina kao modulatori gpr139 Download PDFInfo
- Publication number
- HRP20191003T1 HRP20191003T1 HRP20191003TT HRP20191003T HRP20191003T1 HR P20191003 T1 HRP20191003 T1 HR P20191003T1 HR P20191003T T HRP20191003T T HR P20191003TT HR P20191003 T HRP20191003 T HR P20191003T HR P20191003 T1 HRP20191003 T1 HR P20191003T1
- Authority
- HR
- Croatia
- Prior art keywords
- triazin
- oxobenzo
- acetamide
- ethyl
- methoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082539P | 2014-11-20 | 2014-11-20 | |
| US201562184729P | 2015-06-25 | 2015-06-25 | |
| PCT/US2015/061607 WO2016081736A1 (en) | 2014-11-20 | 2015-11-19 | 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139 |
| EP15816275.0A EP3221298B1 (en) | 2014-11-20 | 2015-11-19 | 4-oxo-3,4-dihydro-1,2,3-benzotriazine derivatives as modulators of gpr139 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191003T1 true HRP20191003T1 (hr) | 2019-08-23 |
Family
ID=55022667
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191003TT HRP20191003T1 (hr) | 2014-11-20 | 2015-11-19 | Derivati 4-okso-3,4-dihidro-1,2,3-benzotriazina kao modulatori gpr139 |
| HRP20212009TT HRP20212009T1 (hr) | 2014-11-20 | 2015-11-19 | 4-okso-3,4-dihidro-1,2,3-benzotriazini kao modulatori gpr139 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20212009TT HRP20212009T1 (hr) | 2014-11-20 | 2015-11-19 | 4-okso-3,4-dihidro-1,2,3-benzotriazini kao modulatori gpr139 |
Country Status (40)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3719B1 (ar) * | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
| US12042496B2 (en) | 2018-10-16 | 2024-07-23 | The University Of Florida Research Foundation, Incorporated | Methods related to opioid therapeutics |
| WO2020097609A1 (en) * | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
| CR20220160A (es) * | 2019-09-16 | 2022-06-16 | Takeda Pharmaceuticals Co | Derivados de piridazin-3(2h)-ona fusionados con azol |
| WO2021127459A1 (en) * | 2019-12-20 | 2021-06-24 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
| JP7697974B2 (ja) * | 2020-05-08 | 2025-06-24 | 武田薬品工業株式会社 | Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物 |
| JP2023541485A (ja) * | 2020-09-21 | 2023-10-02 | 武田薬品工業株式会社 | 統合失調症のための処置 |
| US11760788B2 (en) | 2021-03-02 | 2023-09-19 | Pathways Neuro Pharma, Inc. | Neuroreceptor compositions and methods of use |
| CN116693545A (zh) * | 2022-03-01 | 2023-09-05 | 上海科技大学 | 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用 |
| WO2023165263A1 (zh) * | 2022-03-01 | 2023-09-07 | 上海科技大学 | 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用 |
| CN117986183A (zh) * | 2022-10-28 | 2024-05-07 | 浙江友宁生物医药科技有限公司 | 一种gpr139受体激动剂、其制备方法及其应用 |
| WO2024102802A1 (en) * | 2022-11-11 | 2024-05-16 | Takeda Pharmaceutical Company Limited | Zelatriazin for the treatment of depression |
| WO2025119351A1 (zh) * | 2023-12-08 | 2025-06-12 | 深圳湾实验室 | Gpr139激动剂 |
| WO2025162441A1 (zh) * | 2024-02-02 | 2025-08-07 | 上海科技大学 | 稠杂环类化合物与其制备方法、药物组合物及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3794726A (en) * | 1972-08-21 | 1974-02-26 | Uniroyal Inc | Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one |
| WO1987004928A1 (fr) | 1986-02-24 | 1987-08-27 | Mitsui Petrochemical Industries, Ltd. | Agents therapeutiques de la neuropathie |
| ATE108791T1 (de) | 1987-11-04 | 1994-08-15 | Beecham Group Plc | Neue 4-oxobenzotriazine und 4-oxochinazoline. |
| PE20050630A1 (es) | 2003-06-09 | 2005-09-22 | Boehringer Ingelheim Int | Compuestos heterociclicos como inhibidores del papiloma virus |
| CA2533824A1 (en) | 2003-07-31 | 2005-02-10 | Irm, Llc | Bicyclic compounds and compositions as pdf inhibitors |
| FR2875805B1 (fr) | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
| UY30048A1 (es) | 2005-12-23 | 2007-07-31 | Astrazeneca Ab | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| MX2009010218A (es) * | 2007-03-23 | 2009-10-19 | Hoffmann La Roche | Derivados de aza-piridopirimidinona. |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| JP2016515138A (ja) * | 2013-03-14 | 2016-05-26 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｇｐｒ１３９の生理的リガンド |
| JO3719B1 (ar) * | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
-
2015
- 2015-11-18 JO JOP/2015/0282A patent/JO3719B1/ar active
- 2015-11-19 ES ES15816275T patent/ES2734735T3/es active Active
- 2015-11-19 RS RS20211398A patent/RS62563B1/sr unknown
- 2015-11-19 SM SM20190355T patent/SMT201900355T1/it unknown
- 2015-11-19 TN TN2017000196A patent/TN2017000196A1/en unknown
- 2015-11-19 GE GEAP201514515A patent/GEP20196961B/en unknown
- 2015-11-19 SG SG11201704002UA patent/SG11201704002UA/en unknown
- 2015-11-19 EA EA201791096A patent/EA033728B1/ru unknown
- 2015-11-19 SI SI201530772T patent/SI3221298T1/sl unknown
- 2015-11-19 SM SM20220142T patent/SMT202200142T1/it unknown
- 2015-11-19 KR KR1020177016973A patent/KR102582021B1/ko active Active
- 2015-11-19 RS RS20190776A patent/RS59078B1/sr unknown
- 2015-11-19 ES ES19152036T patent/ES2897545T3/es active Active
- 2015-11-19 PL PL15816275T patent/PL3221298T3/pl unknown
- 2015-11-19 LT LTEP19152036.0T patent/LT3536324T/lt unknown
- 2015-11-19 NZ NZ732208A patent/NZ732208A/en unknown
- 2015-11-19 PE PE2017000866A patent/PE20170899A1/es unknown
- 2015-11-19 CN CN201580071393.8A patent/CN107108531B/zh active Active
- 2015-11-19 MY MYPI2017701778A patent/MY187423A/en unknown
- 2015-11-19 CR CR20170275A patent/CR20170275A/es unknown
- 2015-11-19 EP EP15816275.0A patent/EP3221298B1/en active Active
- 2015-11-19 PL PL19152036T patent/PL3536324T3/pl unknown
- 2015-11-19 LT LTEP15816275.0T patent/LT3221298T/lt unknown
- 2015-11-19 CN CN202010988947.3A patent/CN112062730B/zh active Active
- 2015-11-19 MX MX2017006448A patent/MX378158B/es unknown
- 2015-11-19 PT PT15816275T patent/PT3221298T/pt unknown
- 2015-11-19 CA CA2968242A patent/CA2968242C/en active Active
- 2015-11-19 DK DK19152036.0T patent/DK3536324T3/da active
- 2015-11-19 PT PT191520360T patent/PT3536324T/pt unknown
- 2015-11-19 MA MA40993A patent/MA40993B1/fr unknown
- 2015-11-19 HU HUE15816275A patent/HUE044145T2/hu unknown
- 2015-11-19 AU AU2015349866A patent/AU2015349866B2/en active Active
- 2015-11-19 MD MDE20170117 patent/MD3221298T2/ro unknown
- 2015-11-19 US US14/946,194 patent/US9556130B2/en active Active
- 2015-11-19 SI SI201531729T patent/SI3536324T1/sl unknown
- 2015-11-19 WO PCT/US2015/061607 patent/WO2016081736A1/en not_active Ceased
- 2015-11-19 HR HRP20191003TT patent/HRP20191003T1/hr unknown
- 2015-11-19 UY UY0001036406A patent/UY36406A/es not_active Application Discontinuation
- 2015-11-19 EP EP19152036.0A patent/EP3536324B1/en active Active
- 2015-11-19 JP JP2017526844A patent/JP6637501B2/ja active Active
- 2015-11-19 HR HRP20212009TT patent/HRP20212009T1/hr unknown
- 2015-11-19 HU HUE19152036A patent/HUE057451T2/hu unknown
- 2015-11-19 DK DK15816275.0T patent/DK3221298T3/da active
- 2015-11-19 TW TW104138295A patent/TWI684590B/zh active
- 2015-11-19 UA UAA201705041A patent/UA120375C2/uk unknown
-
2016
- 2016-12-16 US US15/382,490 patent/US9770450B2/en active Active
-
2017
- 2017-05-12 DO DO2017000120A patent/DOP2017000120A/es unknown
- 2017-05-16 IL IL252311A patent/IL252311B/en active IP Right Grant
- 2017-05-18 PH PH12017500920A patent/PH12017500920A1/en unknown
- 2017-05-19 CL CL2017001292A patent/CL2017001292A1/es unknown
- 2017-06-16 CO CONC2017/0005959A patent/CO2017005959A2/es unknown
- 2017-06-20 EC ECIEPI201738999A patent/ECSP17038999A/es unknown
- 2017-08-22 US US15/683,589 patent/US10159677B2/en active Active
-
2018
- 2018-11-02 US US16/179,709 patent/US10561662B2/en active Active
-
2019
- 2019-06-20 CY CY20191100646T patent/CY1122613T1/el unknown
- 2019-12-20 JP JP2019229837A patent/JP6918088B2/ja active Active
-
2020
- 2020-01-02 US US16/732,536 patent/US11173161B2/en active Active
-
2021
- 2021-12-17 CY CY20211101111T patent/CY1124929T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191003T1 (hr) | Derivati 4-okso-3,4-dihidro-1,2,3-benzotriazina kao modulatori gpr139 | |
| JP2017535559A5 (enExample) | ||
| IL199264A (en) | Amide compounds are richly conserved and used for the manufacture of a drug for the treatment of conditions that can be improved by inhibition of poly (adp-ribose) polymerase (parp) | |
| RU2015149528A (ru) | 2-фенилимидазо[1,2-а]пиримидины в качестве визуализирующих средств | |
| JP2012520867A5 (enExample) | ||
| HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
| JP2010529118A5 (enExample) | ||
| IL229199A (en) | N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs | |
| HRP20250088T1 (hr) | Derivati piridazin-3(2h)-ona spojeni s azolom | |
| CL2012001133A1 (es) | Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo. | |
| HRP20210291T1 (hr) | Imunoregulatorna sredstva | |
| SI2935307T1 (en) | Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures | |
| AR067540A1 (es) | Compuesto de aril (isoxazol-4-il-metoxilo) , su uso para preparar un medicamento y composicion farmaceutica que lo comprende | |
| RU2014107486A (ru) | Бициклические пиримидоновые соединения | |
| RU2007146270A (ru) | Гетероциклические ингибиторы hh-сигнального каскада, лекарственные композиции на их основе и способ лечения заболеваний, связанных с абберантной активностью hh сигнальной системы | |
| JP2013544893A5 (enExample) | ||
| HRP20150119T1 (hr) | N-supstituirani derivati glicina kao inhibitori hidroksilaze | |
| RU2006138022A (ru) | Пиримидиновые производные и способы лечения, связанные с их применением | |
| RU2014107484A (ru) | ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2 | |
| NZ609313A (en) | Cyclopropane compounds | |
| Voight et al. | Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature | |
| RU2018112993A (ru) | Соединения и способы для ингибирования JAK | |
| RU2014106611A (ru) | Производные гетероциклических амидов в качестве антагонистов р2х7 рецептора | |
| HRP20161412T1 (hr) | Fluorirani derivati arilalkilaminokarboksamida | |
| DK2422786T3 (da) | Nye lægemiddelkombinationer til behandling af luftvejssygdomme |